Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

BCL2 overexpression in diffuse large B-cell lymphoma.

O Monni1, K Franssila, H Joensuu

  • 1Department of Medical Genetics, Haartman Institute and Helsinki University Central Hospital, University of Helsinki, Finland.

Leukemia & Lymphoma
|June 1, 1999
PubMed
Summary

Translocation (14;18) causes BCL2 overexpression in diffuse large B-cell lymphoma (DLBCL). However, BCL2 overexpression and its impact on DLBCL survival are complex, involving gene amplification and mutations, not just rearrangements.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and/or metastatic solid tumors.

ESMO open·2026
Same author

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>☆</sup>.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST).

ESMO open·2021

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is a significant hematologic malignancy.
  • BCL2 protein overexpression is a hallmark in a subset of DLBCL cases.
  • The translocation t(14;18)(q32;q21) is a primary driver of BCL2 overexpression in DLBCL.

Purpose of the Study:

  • To review BCL2 expression studies in DLBCL.
  • To discuss the mechanisms leading to BCL2 overexpression.
  • To evaluate the prognostic relevance of BCL2 overexpression in DLBCL.

Main Methods:

  • Literature review of studies on BCL2 expression, rearrangement, and amplification in DLBCL.
  • Analysis of data correlating BCL2 overexpression with patient survival.
  • Examination of molecular mechanisms underlying BCL2 dysregulation.

Related Experiment Videos

Main Results:

  • BCL2 overexpression in DLBCL is not solely due to t(14;18); gene amplification and mutations are also implicated.
  • The prognostic significance of BCL2 protein overexpression in DLBCL survival remains controversial, with some studies suggesting a link to poorer outcomes.
  • BCL2 rearrangement itself appears to have a limited association with poor prognosis, though its impact is hard to ascertain due to study variations.

Conclusions:

  • Multiple mechanisms contribute to BCL2 overexpression in DLBCL beyond the canonical t(14;18) translocation.
  • The prognostic value of BCL2 overexpression in DLBCL requires further clarification.
  • Understanding these molecular alterations is crucial for refining DLBCL prognostication and therapeutic strategies.